Statin myopathy

Current Neurology and Neuroscience Reports

Volumn 8, Issue 1, 2008, Pages 66-72

  Radcliffe, Kristofer A ^a   Campbell, William W ^b  

^a MARTIN ARMY COMMUNITY HOSPITAL   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT; ATORVASTATIN; CERIVASTATIN; CHLOROQUINE; CIMETIDINE; COLCHICINE; COMPACTIN; CORTICOSTEROID; CREATINE KINASE; CYCLOSPORIN; CYCLOSPORIN A; DIGOXIN; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; IMMUNOSUPPRESSIVE AGENT; MACROLIDE; METHOTREXATE; MEVINOLIN; NICOTINIC ACID; PITAVASTATIN; PLACEBO; PRAVASTATIN; PREDNISOLONE; ROSUVASTATIN; SIMVASTATIN; UBIDECARENONE; UNINDEXED DRUG; WARFARIN;

ANTISYNTHETASE SYNDROME; CLINICAL FEATURE; DRUG EXCRETION; DRUG MECHANISM; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG WITHDRAWAL; ELECTROMYOGRAM; HUMAN; MUSCLE WEAKNESS; MYALGIA; MYOPATHY; MYOSITIS; PATHOGENESIS; POLYMYOSITIS; REVIEW; RHABDOMYOLYSIS; RISK FACTOR; SIDE EFFECT; SINGLE DRUG DOSE; SYMPTOMATOLOGY;

CREATINE KINASE; DRUG SYNERGISM; EARLY DIAGNOSIS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MUSCLE, SKELETAL; MUSCULAR DISEASES; RHABDOMYOLYSIS; RISK ASSESSMENT; RISK FACTORS;

EID: 38649112673     PISSN: 15284042     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11910-008-0011-4     Document Type: Review

References (46)

1. Thompson PD, Clarkson P, Karas RH: Statin-associated myopathy. JAMA 2003, 289:1681-1690.
2. Baer AN, Wortmann RL: Myotoxicity associated with lipid-lowering drugs. Curr Opin Rheumatol 2007, 19:67-73.
3. Franc S, Dejager S, Bruckert E, et al.: A comprehensive description of muscle symptoms associated with lipid-lowering drugs. Cardiovasc Drugs Ther 2003, 17:459-465.
4. Weffald LA, Flach LA: Myopathy associated with atorvastatin-ezetimibe combination therapy. Pharmacotherapy 2007, 27:309-311.
5. Meas T, Cimadevilla C, Timsit J, et al.: Elevation of CKP induced by ezetimibe in monotherapy: report on two cases. Diabetes Metab 2006, 32:364-366.
6. Simard C, Poirier P: Ezetimibe-associated myopathy in monotherapy and in combination with a 3-hydroxy-3-methyl-glutaryl coenzyme A reductase inhibitor. Can J Cardiol 2006, 22:141-144.
7. Davidson MH, Maccubbin D, Stepanavage M, et al.: Striated muscle safety of ezetimibe/simvastatin (Vytorin). Am J Cardiol 2006, 97:223-228.
8. Schindler C, Thorns M, Matschke K, et al.: Asymptomatic statin-induced rhabdomyolysis after long-term therapy with the hydrophilic drug pravastatin. Clin Ther 2007, 29:172-176.
9. Baker SK, Tarnopolsky MA: Statin-associated neuromyo-toxicity. Drugs Today (Barc) 2005, 41:267-293.
10. Liao JK: Isoprenoids as mediators of the biological effects of statins. J Clin Invest 2002, 110:285-288.
11. Liao JK, Laufs U: Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol 2005, 45:89-118.
12. Liao JK: Clinical implications for statin pleiotropy. Curr Opin Lipidol 2005, 16:624-629.
13. Rundek T, Naini A, Sacco R, et al.: Atorvastatin decreases the coenzyme Q10 level in the blood of patients at risk for cardiovascular disease and stroke. Arch Neurol 2004, 61:889-892.
14. Tokinaga K, Oeda T, Suzuki Y, Matsushima Y: HMG-CoA reductase inhibitors (statins) might cause high elevations of creatine phosphokinase (CK) in patients with unnoticed hypothyroidism. Endocr J 2006, 53:401-405.
15. Vladutiu GD, Simmons Z, Isackson PJ, et al.: Genetic risk factors associated with lipid-lowering drug-induced myopathies. Muscle Nerve 2006, 34:153-162.
16. Jose J, Saravu K, Shastry BA: Atorvastatin-induced early-onset rhabdomyolysis in a patient with nephrotic syndrome. Am J Health Syst Pharm 2007, 64:726-729.
17. Mahboobi SK, Shohat EZ, Jellinek SP, Rose M: Systemic infections can decrease the threshold of statin-induced muscle injury. South Med J 2006, 99:403-404.
18. Oh J, Ban MR, Miskie BA, et al.: Genetic determinants of statin intolerance. Lipids Health Dis 2007, 6:7.
19. Zuccaro P, Mombelli G, Calabresi L, et al.: Tolerability of statins is not linked to CYP450 polymorphisms, but reduced CYP2D6 metabolism improves cholesteraemic response to simvastatin and fluvastatin. Pharmacol Res 2007, 55:310-317.
20. Schmitz G, Langmann T: Pharmacogenomics of cholesterol-lowering therapy. Vasc Pharmacol 2006, 44:75-89.
21. Shitara Y, Sugiyama Y: Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions. Pharmacol Ther 2006, 112:71-105.
22. Bottorff MB: Statin safety and drug interactions: clinical implications. Am J Cardiol 2006, 97:27C-31C.
23. Schmidt GA, Hoehns JD, Purcell JL, et al.: Severe rhabdomyolysis and acute renal failure secondary to concomitant use of simvastatin, amiodarone, and atazanavir. J Am Board Fam Med 2007, 20:411-416.
24. Christopher-Stine L: Statin myopathy: an update. Curr Opin Rheumatol 2006, 18:647-653.
25. Dirks AJ, Jones KM: Statin-induced apoptosis and skeletal myopathy. Am J Physiol Cell Physiol 2006, 291:C1208-C1212.
26. Vasconcelos OM, Campbell WW: Dermatomyositis-like syndrome and HMG-CoA reductase inhibitor (statin) intake. Muscle Nerve 2006, 30:803-807.
27. Hansen KE, Hildebrand JP, Ferguson EE, Stein JH: Outcomes in 45 patients with statin-associated myopathy. Arch Intern Med 2005, 165:2671-2676.
28. Kashani A, Phillips CO, Foody JM, et al.: Risks associated with statin therapy: a systematic overview of randomized clinical trials. Circulation 2006, 114:2788-2797.
29. Phillips PS, Haas RH, Bannykh S, et al.: Statin-associated myopathy with normal creatine kinase levels. Ann Intern Med 2002, 137:581-585.
30. Soininen K, Niemi M, Kilkki E, et al.: Muscle symptoms associated with statins: a series of twenty patients. Basic Clin Pharmacol Toxicol 2006, 98:51-54.
31. Thompson PD, Zmuda JM, Domalik LJ, et al.: Lovastatin increases exercise-induced skeletal muscle injury. Metabolism 1997, 46:1206-1210.
32. Dobkin BH: Statin-related myopathy. Arch Intern Med 2006, 166:1232.
33. Staffa JA, Chang J, Green L: Cerivastatin and reports of fatal rhabdomyolysis. N Engl J Med 2002, 346:539-540.
34. Law M, Rudnicka AR: Statin safety: a systematic review. Am J Cardiol 2006, 97:S52-S60.
35. Antons KA, Williams CD, Baker SK, Phillips PS: Clinical perspectives of statin-induced rhabdomyolysis. Am J Med 2006, 119:400-409.
36. Clark DW, Strandell J: Myopathy including polymyositis: a likely class adverse effect of proton pump inhibitors? Eur J Clin Pharmacol 2006, 62:473-479.
37. Noel B, Panizzon RG: Lupus-like syndrome associated with statin therapy. Dermatology 2004, 208:276-277.
38. Fauchais AL, Iba BJ, Maurage P, et al.: Polymyositis induced or associated with lipid-lowering drugs: five cases [French]. Rev Med Interne 2004, 25:294-298.
39. Needham M, Fabian V, Knezevic W, et al.: Progressive myopathy with up-regulation of MHC-I associated with statin therapy. Neuromusc Disord 2007, 17:194-200.
40. D'Alessandro AM, Mulford GJ: An unusual case of electromyographic recorded myokymic potentials: a case report. Arch Phys Med Rehab 2002, 83:727-729.
41. Gaist D, Jeppesen U, Andersen M, et al.: Statins and risk of polyneuropathy: a case-control study. N Engl J Med 2002, 58:1333-1337.
42. Campbell WW: Statin myopathy: the iceberg or its tip? Muscle Nerve 2006, 34:387-390.
43. Seehusen DA, Asplund CA, Johnson DR, Horde KA: Primary evaluation and management of statin therapy complications. South Med J 2006, 99:250-256.
44. Pasternak RC, Smith SC, Bairey-Merz CN, et al.: ACC/AHA/NHLBI clinical advisory on the use and safety of statins. Stroke 2002, 33:2337-2341.
45. Marcoff L, Thompson PD: The role of coenzyme Q10 in statin-associated myopathy: a systematic review. J Am Coll Cardiol 2007, 49:2231-2237.
46. Caso G, Kelly P, McNurlan MA, Lawson WE: Effect of coenzyme Q10 on myopathic symptoms in patients treated with statins. Am J Cardiol 2007, 99:1409-1412.